Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Neoleukin Therapeutics, Inc. NLTX NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
30/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Neoleukin Therapeutics, Inc. (NLTX) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 5 Buy, 8 Hold, 1 Sell.

NLTX Analyst Ratings

Hold
14
Ratings
5 Buy
8 Hold
1 Sell
Based on 14 analysts giving stock ratings to Neoleukin Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
5 36%
Hold
8 57%
Sell
1 7%
36%
Buy
5 analysts
57%
Hold
8 analysts
7%
Sell
1 analysts

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message